Role of anti‐domain 1‐β2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jth.13389PMID 27314634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk

  2015cited by this paper
• Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome.

  2015cited by this paper
• Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation

  2014cited by this paper
• New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies

  2014cited by this paper
• 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

  2014cited by this paper
• Testing for Antiphospholipid antibodies with Solid Phase Assays: guidance from the SSC of the ISTH

  2014cited by this paper
• Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.

  2014cited by this paper
• Standardization of Antiphospholipid Antibody Testing—Historical Perspectives and Ongoing Initiatives

  2014cited by this paper
• Domain I: the hidden face of antiphospholipid syndrome

  2014cited by this paper
• Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti–beta2 glycoprotein‐1 antibodies

  2014cited by this paper
• Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs

  2013cited by this paper
• Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile

  2013cited by this paper
• Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome

  2012cited by this paper
• Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome

  2012cited by this paper
• Antiphospholipid antibodies: evaluation of the thrombotic risk.

  2012cited by this paper
• Standardization of antiphospholipid antibody assays. Where do we stand?

  2012cited by this paper
• Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome.

  2012cited by this paper
• Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.

  2012cited by this paper
• Antibodies against domain I of β2-glycoprotein I: the one and only?

  2012cited by this paper
• Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS).

  2011cited by this paper
• Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays.

  2011cited by this paper
• Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome

  2010cited by this paper
• Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?

  2010cited by this paper
• Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy.

  2009cited by this paper
• The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study

  2009cited by this paper
• Update of the guidelines for lupus anticoagulant detection

  2009cited by this paper
• Influence of different IgG anticardiolipin antibody cut‐off values on antiphospholipid syndrome classification

  2008cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change.

  2006cited by this paper
• The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant

  2005cited by this paper
• Antibody profiles for the diagnosis of antiphospholipid syndrome

  2005cited by this paper
• IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.

  2005cited by this paper
• Pathogenic anti- β 2 -glycoprotein I antibodies recognize domain I of β 2 -glycoprotein I only after a conformational change

  2005cited by this paper
• beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

  2004cited by this paper
• Use of Single Point Mutations in Domain I of β2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies1

  2002cited by this paper
• Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

  1990cited by this paper
• Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

  1990cited by this paper
• Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

  1990cited by this paper

• The diagnostic and prognostic values of non-criteria antiphospholipid antibodies in obstetric antiphospholipid syndrome

  2026cites this paper
• Distribution of HLA-DRB1 Alleles in Patients With Antiphospholipid Syndrome and Their Association With Antiphospholipid Antibodies Presence and Damage Indexes

  2025cites this paper
• Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis

  2025cites this paper
• The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus.

  2024cites this paper
• Antibody profiles in the mosaic of "seronegative" APS syndrome.

  2024cites this paper
• Noncriteria antiphospholipid antibodies in antiphospholipid syndrome

  2024cites this paper
• Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China

  2023cites this paper
• Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Antibodies Toward the Domain I of Beta2-Glycoprotein I (aDI).

  2023cites this paper
• Evolution of Antiphospholipid Syndrome

  2023cites this paper
• Relations between antinuclear, antineutrophil cytoplasmic, anticardiolipin antibodies and degree of neurological deficit, cerebrovascular stenosis in cerebral infarction patients

  2023cites this paper
• Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?

  2023cites this paper
• Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain.

  2023cites this paper
• Solid Phase Assays for Antiphospholipid Antibodies.

  2022cites this paper
• Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus

  2022cites this paper
• Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances

  2022cites this paper
• Laboratory Approaches to Test the Function of Antiphospholipid Antibodies

  2021cites this paper
• Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome

  2021cites this paper
• Extra criterial antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data)

  2021cites this paper
• Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

  2021cites this paper
• Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review).

  2021cites this paper
• [Seronegative antiphospholipid syndrome: Myth or reality?]

  2020cites this paper
• Non-criteria Antiphospholipid Antibodies: a narrative review.

  2020cites this paper
• Multiplex-EIA systemを利用した抗リン脂質抗体スクリーニング検査システムの検討

  2020cites this paper
• Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis

  2020cites this paper
• How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome.

  2020cites this paper
• 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

  2020cites this paper
• Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.

  2020cites this paper
• How to Interpret Antiphospholipid Laboratory Tests

  2020cites this paper
• Testing for antiphospholipid antibodies: Advances and best practices

  2020cites this paper
• Anti‐phospholipid antibodies and reproductive failures

  2020cites this paper
• Diagnostic biologique du syndrome des antiphospholipides

  2020cites this paper
• Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study

  2020cites this paper
• The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS

  2020cites this paper
• Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro

  2020cites this paper
• Does seronegative obstetric APS exist? "pro" and "cons".

  2019cites this paper
• Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients

  2019cites this paper
• News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination.

  2019cites this paper
• Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?

  2019cites this paper
• Laboratory Evaluation of Antiphospholipid Syndrome.

  2019cites this paper
• Laboratory Evaluation of Antiphospholipid Syndrome: An Update on Autoantibody Testing.

  2019cites this paper
• Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study

  2019cites this paper
• Role of anti-domain I β2-glycoprotein I antibodies measured by different methods, in the diagnosis and risk stratification of antiphospholipid syndrome Subcommittee on Lupus anticoagulant/ antiphospholipid antibodies

  2018cites this paper
• Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome.

  2018cites this paper
• Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria

  2018cites this paper
• Antiphospholipid syndrome

  2018cites this paper
• University of Birmingham Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis

  2018cites this paper
• Clinical profiles and risk assessment in patients with antiphospholipid antibodies

  2018cites this paper
• Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH

  2018cites this paper
• Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus

  2018cites this paper
• The clinical value of assays detecting antibodies against domain I of β2-glycoprotein I in the antiphospholipid syndrome.

  2018cites this paper
• First‐Line, Non‐Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti–β2‐Glycoprotein I Domain I and Anti–Phosphatidylserine/Prothrombin Complex Antibodies Tests

  2018cites this paper
• Update on Antiphospholipid Syndrome: Ten Topics in 2017

  2018cites this paper
• La ricerca del lupus anticoagulant: raccomandazioni del gruppo di studio sulla coagulazione di SIPMeL

  2018cites this paper
• Antiphospholipid syndrome - an update.

  2018cites this paper
• Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

  2018cites this paper
• Laboratory criteria for antiphospholipid syndrome: reply

  2018cites this paper
• Effects of anti‐β2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity

  2018cites this paper
• Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study.

  2018cites this paper
• Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?

  2018cites this paper
• Assessment of diagnostic methods for the detection of anticardiolipin and anti-βeta2 glycoprotein I antibodies in patients under routine evaluation for antiphospholipid syndrome.

  2018cites this paper
• [Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice].

  2018cites this paper
• Triple positive and seronegative antiphospholipid syndrome: The same disorder?

  2018cites this paper
• The Laboratory Diagnosis of the Antiphospholipid Syndrome

  2017cites this paper
• Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk

  2017cites this paper
• Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests

  2017cites this paper
• The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome

  2017cites this paper
• Immunotherapeutic strategies in antiphospholipid syndrome

  2017cites this paper
• Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.

  2017cites this paper
• Diagnosis and management of the antiphospholipid syndrome.

  2017cites this paper
• β2-glycoprotein I and its antibodies involve in the pathogenesis of the antiphospholipid syndrome.

  2017cites this paper
• How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores

  2017cites this paper
• Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances

  2017cites this paper
• Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers

  2017cites this paper
• [The scoring system for the risk-stratification in patients with the antiphospholipid syndrome].

  2017cites this paper
• Detection of antibodies against domain 1 of β2-glycoprotein I is key in predicting thromboembolic complications in patients with systemic lupus erythematosus.

  2017cites this paper
• Role of anti‐domain 1‐ß2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: reply

  2016cites this paper
• Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome.

  2016cites this paper
• Role of anti‐domain 1‐ β2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: comment

  2016cites this paper
• Title : The impact of antiphospholipid antibodies/antiphospholipid syndrome on SLE

  year unknowncites this paper